231 related articles for article (PubMed ID: 28699529)
1. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
Zhou A
Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
[TBL] [Abstract][Full Text] [Related]
2. Targeting multiple kinases in glioblastoma multiforme.
Sathornsumetee S; Reardon DA
Expert Opin Investig Drugs; 2009 Mar; 18(3):277-92. PubMed ID: 19243279
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology.
de Almeida Magalhães T; de Sousa GR; Alencastro Veiga Cruzeiro G; Tone LG; Valera ET; Borges KS
J Mol Med (Berl); 2020 Apr; 98(4):495-512. PubMed ID: 32219470
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies to target multiple kinases in glioblastoma.
Sathornsumetee S
Anticancer Agents Med Chem; 2011 Oct; 11(8):700-11. PubMed ID: 21707500
[TBL] [Abstract][Full Text] [Related]
5. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
6. Protein Kinases as Tumor Biomarkers and Therapeutic Targets.
Quan C; Xiao J; Liu L; Duan Q; Yuan P; Zhu F
Curr Pharm Des; 2017 Nov; 23(29):4209-4225. PubMed ID: 28730960
[TBL] [Abstract][Full Text] [Related]
7. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
Panner A; Parsa AT; Pieper RO
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1313-22. PubMed ID: 17020463
[TBL] [Abstract][Full Text] [Related]
8. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.
Yuan J; Zhang F; Hallahan D; Zhang Z; He L; Wu LG; You M; Yang Q
J Exp Clin Cancer Res; 2018 Aug; 37(1):181. PubMed ID: 30071868
[TBL] [Abstract][Full Text] [Related]
10. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
11. Eph receptors as therapeutic targets in glioblastoma.
Day BW; Stringer BW; Boyd AW
Br J Cancer; 2014 Sep; 111(7):1255-61. PubMed ID: 25144626
[TBL] [Abstract][Full Text] [Related]
12. Deregulated signalling networks in human brain tumours.
Grzmil M; Hemmings BA
Biochim Biophys Acta; 2010 Mar; 1804(3):476-83. PubMed ID: 19879382
[TBL] [Abstract][Full Text] [Related]
13. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
14. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
15. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
[TBL] [Abstract][Full Text] [Related]
17. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
Bhusare N; Kumar M
Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
[TBL] [Abstract][Full Text] [Related]
18. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
19. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]